Genomic features of de novo metastatic prostate cancer can clarify prognosis and direct therapy. Using multi-region profiling of synchronous primary and metastatic patient tissues, we reveal the complex evolutionary histories of this lethal disease and identify strategies to better capture the genomic features of dominant metastatic populations.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 digital issues and online access to articles
$119.00 per year
only $9.92 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Helgstrand, J. T. et al. Trends in incidence and 5-year mortality in men with newly diagnosed, metastatic prostate cancer-A population-based analysis of 2 national cohorts. Cancer 124, 2931–2938 (2018). This paper describes the survival of individuals with de novo metastatic prostate cancer from two cohorts in the USA and Denmark.
Espiritu, S. M. G. et al. The evolutionary landscape of localized prostate cancers drives clinical aggression. Cell 173, 1003–1013.e15 (2018). This study reports that heterogeneity within localized prostate cancers is associated with poor prognosis. It uses samples obtained from radical surgery, which are commonly available in the localized setting.
Mateo, J. et al. Genomics of lethal prostate cancer at diagnosis and castration resistance. J. Clin. Invest. 130, 1743–1751 (2020). This paper reports on the genomic landscape of metastatic prostate cancer and tracks cancer evolution from a single biopsy at diagnosis to a biopsy at treatment resistance.
Stopsack, K. H. et al. oncogenic genomic alterations, clinical phenotypes, and outcomes in metastatic castration-sensitive prostate cancer. Clin. Cancer Res. 26, 3230–3238 (2020). This paper reports the common genomic alterations and corresponding clinical correlates in metastatic castration-sensitive prostate cancer using a single biopsy sample.
Sathianathen, N. J. et al. Emergence of triplet therapy for metastatic castration-sensitive prostate cancer: an updated systematic review and network meta-analysis. Urologic Oncol. 41, 233–239 (2023). A review article presenting the treatment landscape of metastatic prostate cancer.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
This is a summary of: Warner, E. W. et al. Multiregion sampling of de novo metastatic prostate cancer reveals complex polyclonality and augments clinical genotyping. Nat. Cancer https://doi.org/10.1038/s43018-023-00692-y (2024).
Rights and permissions
About this article
Cite this article
Towards accurate genomics for newly diagnosed metastatic prostate cancer. Nat Cancer 5, 8–9 (2024). https://doi.org/10.1038/s43018-023-00693-x
Published:
Issue Date:
DOI: https://doi.org/10.1038/s43018-023-00693-x
